Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
51
NAMS Quote, Financials, Valuation and Earnings
Last price:
$35.47
Seasonality move
:
-4.57%
Day range:
$33.24 - $35.00
52-week range:
$14.06 - $42.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
178.26x
P/B ratio:
5.77x
Volume:
900.9K
Avg. volume:
676K
1-year change:
73.92%
Market cap:
$3.9B
Revenue:
$22.5M
EPS (TTM):
-$1.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NAMS
NewAmsterdam Pharma Co. NV
|
$2.9M | -$0.43 | -60.56% | -48.71% | $48.95 |
|
ARGX
argenx SE
|
$1.3B | $6.19 | 87.13% | 205.62% | $1,031.68 |
|
PHAR
Pharming Group NV
|
$106.1M | $0.01 | 17.76% | -100% | $31.00 |
|
PHVS
Pharvaris NV
|
-- | -$0.72 | -- | -15.87% | $46.30 |
|
PRQR
ProQR Therapeutics NV
|
$6.1M | -$0.17 | 17.05% | -55.96% | $8.88 |
|
QURE
uniQure NV
|
$5.6M | -$0.93 | 339.4% | -13.99% | $53.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NAMS
NewAmsterdam Pharma Co. NV
|
$34.28 | $48.95 | $3.9B | -- | $0.00 | 0% | 178.26x |
|
ARGX
argenx SE
|
$771.53 | $1,031.68 | $47.7B | 42.59x | $0.00 | 0% | 16.45x |
|
PHAR
Pharming Group NV
|
$16.37 | $31.00 | $1.1B | 1,144.76x | $0.00 | 0% | 3.08x |
|
PHVS
Pharvaris NV
|
$28.00 | $46.30 | $1.8B | -- | $0.00 | 0% | -- |
|
PRQR
ProQR Therapeutics NV
|
$1.59 | $8.88 | $167.5M | -- | $0.00 | 0% | 9.62x |
|
QURE
uniQure NV
|
$17.12 | $53.52 | $1.1B | -- | $0.00 | 0% | 58.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NAMS
NewAmsterdam Pharma Co. NV
|
0.03% | 1.199 | 0.01% | 7.43x |
|
ARGX
argenx SE
|
-- | 0.022 | -- | 4.92x |
|
PHAR
Pharming Group NV
|
33.1% | 0.932 | 13.18% | 2.39x |
|
PHVS
Pharvaris NV
|
0.19% | -0.126 | 0.04% | 12.56x |
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.348 | 7.64% | 3.23x |
|
QURE
uniQure NV
|
69.92% | 7.217 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NAMS
NewAmsterdam Pharma Co. NV
|
-$27K | -$66M | -27.35% | -27.36% | -206187.5% | -$41M |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
PHVS
Pharvaris NV
|
-$122.9K | -$46.3M | -62.86% | -63% | -- | -$38.2M |
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
NewAmsterdam Pharma Co. NV vs. Competitors
-
Which has Higher Returns NAMS or ARGX?
argenx SE has a net margin of -234134.38% compared to NewAmsterdam Pharma Co. NV's net margin of 25.88%. NewAmsterdam Pharma Co. NV's return on equity of -27.36% beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital NAMSNewAmsterdam Pharma Co. NV-84.38% -$0.65 $683.6M ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About NAMS or ARGX?
NewAmsterdam Pharma Co. NV has a consensus price target of $48.95, signalling upside risk potential of 42.81%. On the other hand argenx SE has an analysts' consensus of $1,031.68 which suggests that it could grow by 33.72%. Given that NewAmsterdam Pharma Co. NV has higher upside potential than argenx SE, analysts believe NewAmsterdam Pharma Co. NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings NAMSNewAmsterdam Pharma Co. NV10 1 0 ARGXargenx SE15 1 0 -
Is NAMS or ARGX More Risky?
NewAmsterdam Pharma Co. NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison argenx SE has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.596%.
-
Which is a Better Dividend Stock NAMS or ARGX?
NewAmsterdam Pharma Co. NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewAmsterdam Pharma Co. NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAMS or ARGX?
NewAmsterdam Pharma Co. NV quarterly revenues are $32K, which are smaller than argenx SE quarterly revenues of $948M. NewAmsterdam Pharma Co. NV's net income of -$74.9M is lower than argenx SE's net income of $245.4M. Notably, NewAmsterdam Pharma Co. NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 42.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewAmsterdam Pharma Co. NV is 178.26x versus 16.45x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAMSNewAmsterdam Pharma Co. NV178.26x -- $32K -$74.9M ARGXargenx SE16.45x 42.59x $948M $245.4M
-
Which has Higher Returns NAMS or PHAR?
Pharming Group NV has a net margin of -234134.38% compared to NewAmsterdam Pharma Co. NV's net margin of 7.71%. NewAmsterdam Pharma Co. NV's return on equity of -27.36% beat Pharming Group NV's return on equity of 0.39%.
Company Gross Margin Earnings Per Share Invested Capital NAMSNewAmsterdam Pharma Co. NV-84.38% -$0.65 $683.6M PHARPharming Group NV92.7% $0.11 $395.6M -
What do Analysts Say About NAMS or PHAR?
NewAmsterdam Pharma Co. NV has a consensus price target of $48.95, signalling upside risk potential of 42.81%. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 89.37%. Given that Pharming Group NV has higher upside potential than NewAmsterdam Pharma Co. NV, analysts believe Pharming Group NV is more attractive than NewAmsterdam Pharma Co. NV.
Company Buy Ratings Hold Ratings Sell Ratings NAMSNewAmsterdam Pharma Co. NV10 1 0 PHARPharming Group NV3 0 0 -
Is NAMS or PHAR More Risky?
NewAmsterdam Pharma Co. NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharming Group NV has a beta of -0.009, suggesting its less volatile than the S&P 500 by 100.89%.
-
Which is a Better Dividend Stock NAMS or PHAR?
NewAmsterdam Pharma Co. NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewAmsterdam Pharma Co. NV pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAMS or PHAR?
NewAmsterdam Pharma Co. NV quarterly revenues are $32K, which are smaller than Pharming Group NV quarterly revenues of $96.9M. NewAmsterdam Pharma Co. NV's net income of -$74.9M is lower than Pharming Group NV's net income of $7.5M. Notably, NewAmsterdam Pharma Co. NV's price-to-earnings ratio is -- while Pharming Group NV's PE ratio is 1,144.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewAmsterdam Pharma Co. NV is 178.26x versus 3.08x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAMSNewAmsterdam Pharma Co. NV178.26x -- $32K -$74.9M PHARPharming Group NV3.08x 1,144.76x $96.9M $7.5M
-
Which has Higher Returns NAMS or PHVS?
Pharvaris NV has a net margin of -234134.38% compared to NewAmsterdam Pharma Co. NV's net margin of --. NewAmsterdam Pharma Co. NV's return on equity of -27.36% beat Pharvaris NV's return on equity of -63%.
Company Gross Margin Earnings Per Share Invested Capital NAMSNewAmsterdam Pharma Co. NV-84.38% -$0.65 $683.6M PHVSPharvaris NV-- -$0.70 $367.6M -
What do Analysts Say About NAMS or PHVS?
NewAmsterdam Pharma Co. NV has a consensus price target of $48.95, signalling upside risk potential of 42.81%. On the other hand Pharvaris NV has an analysts' consensus of $46.30 which suggests that it could grow by 65.34%. Given that Pharvaris NV has higher upside potential than NewAmsterdam Pharma Co. NV, analysts believe Pharvaris NV is more attractive than NewAmsterdam Pharma Co. NV.
Company Buy Ratings Hold Ratings Sell Ratings NAMSNewAmsterdam Pharma Co. NV10 1 0 PHVSPharvaris NV8 1 0 -
Is NAMS or PHVS More Risky?
NewAmsterdam Pharma Co. NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NAMS or PHVS?
NewAmsterdam Pharma Co. NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewAmsterdam Pharma Co. NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAMS or PHVS?
NewAmsterdam Pharma Co. NV quarterly revenues are $32K, which are larger than Pharvaris NV quarterly revenues of --. NewAmsterdam Pharma Co. NV's net income of -$74.9M is lower than Pharvaris NV's net income of -$43.4M. Notably, NewAmsterdam Pharma Co. NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewAmsterdam Pharma Co. NV is 178.26x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAMSNewAmsterdam Pharma Co. NV178.26x -- $32K -$74.9M PHVSPharvaris NV-- -- -- -$43.4M
-
Which has Higher Returns NAMS or PRQR?
ProQR Therapeutics NV has a net margin of -234134.38% compared to NewAmsterdam Pharma Co. NV's net margin of -381.88%. NewAmsterdam Pharma Co. NV's return on equity of -27.36% beat ProQR Therapeutics NV's return on equity of -67.34%.
Company Gross Margin Earnings Per Share Invested Capital NAMSNewAmsterdam Pharma Co. NV-84.38% -$0.65 $683.6M PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M -
What do Analysts Say About NAMS or PRQR?
NewAmsterdam Pharma Co. NV has a consensus price target of $48.95, signalling upside risk potential of 42.81%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 458.18%. Given that ProQR Therapeutics NV has higher upside potential than NewAmsterdam Pharma Co. NV, analysts believe ProQR Therapeutics NV is more attractive than NewAmsterdam Pharma Co. NV.
Company Buy Ratings Hold Ratings Sell Ratings NAMSNewAmsterdam Pharma Co. NV10 1 0 PRQRProQR Therapeutics NV7 0 0 -
Is NAMS or PRQR More Risky?
NewAmsterdam Pharma Co. NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.200, suggesting its less volatile than the S&P 500 by 79.991%.
-
Which is a Better Dividend Stock NAMS or PRQR?
NewAmsterdam Pharma Co. NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewAmsterdam Pharma Co. NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAMS or PRQR?
NewAmsterdam Pharma Co. NV quarterly revenues are $32K, which are smaller than ProQR Therapeutics NV quarterly revenues of $3.4M. NewAmsterdam Pharma Co. NV's net income of -$74.9M is lower than ProQR Therapeutics NV's net income of -$12.9M. Notably, NewAmsterdam Pharma Co. NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewAmsterdam Pharma Co. NV is 178.26x versus 9.62x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAMSNewAmsterdam Pharma Co. NV178.26x -- $32K -$74.9M PRQRProQR Therapeutics NV9.62x -- $3.4M -$12.9M
-
Which has Higher Returns NAMS or QURE?
uniQure NV has a net margin of -234134.38% compared to NewAmsterdam Pharma Co. NV's net margin of -2175.87%. NewAmsterdam Pharma Co. NV's return on equity of -27.36% beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital NAMSNewAmsterdam Pharma Co. NV-84.38% -$0.65 $683.6M QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About NAMS or QURE?
NewAmsterdam Pharma Co. NV has a consensus price target of $48.95, signalling upside risk potential of 42.81%. On the other hand uniQure NV has an analysts' consensus of $53.52 which suggests that it could grow by 212.7%. Given that uniQure NV has higher upside potential than NewAmsterdam Pharma Co. NV, analysts believe uniQure NV is more attractive than NewAmsterdam Pharma Co. NV.
Company Buy Ratings Hold Ratings Sell Ratings NAMSNewAmsterdam Pharma Co. NV10 1 0 QUREuniQure NV9 4 0 -
Is NAMS or QURE More Risky?
NewAmsterdam Pharma Co. NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.669%.
-
Which is a Better Dividend Stock NAMS or QURE?
NewAmsterdam Pharma Co. NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewAmsterdam Pharma Co. NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAMS or QURE?
NewAmsterdam Pharma Co. NV quarterly revenues are $32K, which are smaller than uniQure NV quarterly revenues of $3.7M. NewAmsterdam Pharma Co. NV's net income of -$74.9M is higher than uniQure NV's net income of -$80.5M. Notably, NewAmsterdam Pharma Co. NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewAmsterdam Pharma Co. NV is 178.26x versus 58.48x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAMSNewAmsterdam Pharma Co. NV178.26x -- $32K -$74.9M QUREuniQure NV58.48x -- $3.7M -$80.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
